Cogent Biosciences Announces Participation at Upcoming Investor Conferences
01 févr. 2023 08h00 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
09 janv. 2023 08h00 HE
|
Cogent Biosciences, Inc.
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from...
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
05 janv. 2023 08h00 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
11 déc. 2022 17h30 HE
|
Cogent Biosciences, Inc.
- 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up - Rapid and deep responses seen including first confirmed CR at 20 weeks; 77% of patients...
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
05 déc. 2022 08h00 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
28 nov. 2022 16h15 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
14 nov. 2022 07h00 HE
|
Cogent Biosciences, Inc.
Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in...
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
09 nov. 2022 08h00 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
03 nov. 2022 09h05 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
26 oct. 2022 07h00 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...